Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Labeled, Multiple Dose, 2-Sequence, 2-Period Cross-over Phase 1 Study to Evaluate the Drug-Drug Interaction of PK101-001 and PK101-002 in Healthy Volunteers.

NCT03553316 is registered in ClinicalTrials.gov with PMG Pharm Co., Ltd as lead sponsor.

NCT NCT03553316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03553316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Labeled, Multiple Dose, 2-Sequence, 2-Period Cross-over Phase 1 Study to Evaluate the Drug-Drug Interaction of PK101-001 and PK101-002 in Healthy Volunteers.
Lead sponsor
PMG Pharm Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2019
Completion date
April 24, 2019
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis